| Name | Title | Contact Details |
|---|
Davids Productions is a Montville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Carta empowers hospitals to personalize the delivery of care to the individual needs of each patient. Our insight here is that personalizing care is not only good from an outcome/clinical perspective (where most people focus in the context of personalization) but is also the best way to optimize operations. Currently, hospitals have to over provision their resources because they are set up to serve the generic patient; planning ahead for exactly the resources needed– no more, no less– is the best way to gain efficiency. The approach we`re advocating and enabling is to: 1) Find past patients similar to the current one being treated 2) Quantify what exactly happened to them during their journey through the hospital (this is where our model comes in) 3) Use machine learning to project what the particular patient in question will need, and what the patient can expect their experience to be in the hospital We`re applying this approach now to two use cases– supplies projection and bed usage projection– and we have a bunch of other use cases we`re planning on addressing in the future.
Netwal Dental Laboratory Inc is a La Crosse, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.